Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338221 | 0.94 | DPP4 (0.39) | BRD4BRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17001968 | 0.92 | DPP4 (0.39) | BRD4BRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12309469 | 0.89 | KDM5A (0.42) | BRD4BRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20465779 | 0.88 | CHRM2 (0.41) | BRD4BRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17185334 | 0.85 | — | — | |
| SCHEMBL6335314 | 0.83 | NOS3 (0.45) | BRD4BRD2NOS3NOS1NPY5R | |
| SCHEMBL11842283 | 0.83 | NOS3 (0.45) | BRD4BRD2KDM5ANOS3NOS1 | |
| SCHEMBL15242574 | 0.82 | BRD4 (0.46) | BRD4BRD2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23917218 | 0.81 | NOS3 (0.43) | BRD4BRD2NOS3NOS1NPY5R | |
| SCHEMBL22889 | 0.81 | NOS3 (0.43) | BRD4BRD2NOS3NOS1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897778-B2 | Benzamide compounds | ASTRAZENECA (SE) | 2011-03-01 | — | — | US | claimed |
| US-20080293687-A1 | Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| WO-2008100618-A2 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2023168291-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| WO-2021076886-A1 | 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-25 | — | — | US | disclosed |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-7223780-B2 | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| WO-2007036532-A2 | SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-7196103-B2 | Indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-27 | — | — | US | disclosed |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
| WO-2006024841-A2 | BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329263-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | BRD4 1927/4885BRD2 1845/4885CHRNB2 4014/4885 |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | BRD4 1380/4885BRD2 3166/4885CHRNB2 4670/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | BRD4 381/4885BRD2 2032/4885CHRNB2 4138/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | BRD4 848/4885BRD2 1091/4885CHRNB2 381/4885 |
| US-20070049573-A1 | Pyrrole-Derivatives as Factor Xa Inhibitors | F12, F2, F5 | BRD4 2817/4885BRD2 4036/4885CHRNB2 4557/4885 |
| US-20210147385-A1 | COMPOUNDS AND METHODS FOR TARGETING PATHOGENIC BLOOD VESSELS | TEK, KDR, LIPG | BRD4 3909/4885BRD2 3083/4885CHRNB2 1610/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | BRD4 501/4885BRD2 1542/4885CHRNB2 4311/4885 |
| US-20080293687-A1 | Benzamide Compounds | HDAC1, HDAC11, HDAC2 | BRD4 47/4885BRD2 71/4885CHRNB2 3212/4885 |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | BRD4 3936/4885BRD2 4343/4885CHRNB2 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.